Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

cbdMD, Inc.

YCBDAMEX
Healthcare
Drug Manufacturers - Specialty & Generic
$0.72
$0.01(1.41%)
U.S. Market opens in 15h 58m

cbdMD, Inc. Fundamental Analysis

cbdMD, Inc. (YCBD) shows weak financial fundamentals with a PE ratio of -2.75, profit margin of -12.25%, and ROE of -40.66%. The company generates $0.0B in annual revenue with weak year-over-year growth of -1.50%.

Key Strengths

Cash Position52.25%
PEG Ratio-0.12
Current Ratio2.94

Areas of Concern

ROE-40.66%
Operating Margin-12.37%
We analyze YCBD's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -69.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-69.0/100

We analyze YCBD's fundamental strength across five key dimensions:

Efficiency Score

Weak

YCBD struggles to generate sufficient returns from assets.

ROA > 10%
-19.85%

Valuation Score

Excellent

YCBD trades at attractive valuation levels.

PE < 25
-2.75
PEG Ratio < 2
-0.12

Growth Score

Moderate

YCBD shows steady but slowing expansion.

Revenue Growth > 5%
-1.50%
EPS Growth > 10%
39.11%

Financial Health Score

Moderate

YCBD shows balanced financial health with some risks.

Debt/Equity < 1
65.83
Current Ratio > 1
2.94

Profitability Score

Weak

YCBD struggles to sustain strong margins.

ROE > 15%
-4066.21%
Net Margin ≥ 15%
-12.25%
Positive Free Cash Flow
No

Key Financial Metrics

Is YCBD Expensive or Cheap?

P/E Ratio

YCBD trades at -2.75 times earnings. This suggests potential undervaluation.

-2.75

PEG Ratio

When adjusting for growth, YCBD's PEG of -0.12 indicates potential undervaluation.

-0.12

Price to Book

The market values cbdMD, Inc. at 0.71 times its book value. This may indicate undervaluation.

0.71

EV/EBITDA

Enterprise value stands at 1190.01 times EBITDA. This signals the market has high growth expectations.

1190.01

How Well Does YCBD Make Money?

Net Profit Margin

For every $100 in sales, cbdMD, Inc. keeps $-12.25 as profit after all expenses.

-12.25%

Operating Margin

Core operations generate -12.37 in profit for every $100 in revenue, before interest and taxes.

-12.37%

ROE

Management delivers $-40.66 in profit for every $100 of shareholder equity.

-40.66%

ROA

cbdMD, Inc. generates $-19.85 in profit for every $100 in assets, demonstrating efficient asset deployment.

-19.85%

Following the Money - Real Cash Generation

Operating Cash Flow

cbdMD, Inc. generates limited operating cash flow of $-2.27M, signaling weaker underlying cash strength.

$-2.27M

Free Cash Flow

cbdMD, Inc. generates weak or negative free cash flow of $-193.45M, restricting financial flexibility.

$-193.45M

FCF Per Share

Each share generates $-18.43 in free cash annually.

$-18.43

FCF Yield

YCBD converts -21.98% of its market value into free cash.

-21.98%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-2.75

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.12

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.71

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.39

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

65.83

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.94

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.41

vs 25 benchmark

ROA

Return on assets percentage

-0.20

vs 25 benchmark

ROCE

Return on capital employed

-0.26

vs 25 benchmark

How YCBD Stacks Against Its Sector Peers

MetricYCBD ValueSector AveragePerformance
P/E Ratio-2.7528.25 Better (Cheaper)
ROE-40.66%780.00% Weak
Net Margin-12.25%-20122.00% (disorted) Weak
Debt/Equity65.830.30 Weak (High Leverage)
Current Ratio2.944.66 Strong Liquidity
ROA-19.85%-14687.00% (disorted) Weak

YCBD outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews cbdMD, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-88.83%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-103.95%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

96.68%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ